Respiratory Syncytial Virus Infections Clinical Trials

11 recruitingLast updated: May 13, 2026

There are 11 actively recruiting respiratory syncytial virus infections clinical trials across 14 countries. Studies span Phase 2, Phase 3, Phase 1. Top locations include Omaha, Nebraska, United States, St Louis, Missouri, United States, Cleveland, Ohio, United States. Updated daily from ClinicalTrials.gov.


Respiratory Syncytial Virus Infections Trials at a Glance

11 actively recruiting trials for respiratory syncytial virus infections are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Omaha, St Louis, and Cleveland. Lead sponsors running respiratory syncytial virus infections studies include GlaxoSmithKline, Blue Lake Biotechnology Inc., and Assistance Publique - Hôpitaux de Paris.

Browse respiratory syncytial virus infections trials by phase

About Respiratory Syncytial Virus Infections Clinical Trials

Looking for clinical trials for Respiratory Syncytial Virus Infections? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Respiratory Syncytial Virus Infections trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Respiratory Syncytial Virus Infections clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Respiratory Syncytial Virus Infections
Shionogi192 enrolled68 locationsNCT07214571
Recruiting
Phase 3

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Infections
GlaxoSmithKline750 enrolled13 locationsNCT07220109
Recruiting
Phase 2

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

Respiratory Syncytial Virus Infections
GlaxoSmithKline184 enrolled37 locationsNCT07092865
Recruiting
Phase 3

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

Respiratory Syncytial Virus Infections
University of Alabama at Birmingham370 enrolled15 locationsNCT05026749
Recruiting
Phase 1Phase 2

A Study of BLB-201 RSV Vaccine in Infants and Children

Respiratory Syncytial Virus Infections
Blue Lake Biotechnology Inc.137 enrolled11 locationsNCT05655182
Recruiting
Phase 3

RSV Vaccine in Transplant Recipients

Immune SuppressionVaccine Response ImpairedRespiratory Syncytial Virus Infections
University Health Network, Toronto100 enrolled1 locationNCT06593210
Recruiting

Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus Infection
Tam Anh Research Institute1,000 enrolled1 locationNCT07239583
Recruiting
Phase 1Phase 2

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

SARS CoV-2Respiratory distress syndromeInfluenza, Human+1 more
PEACHES BIOTECH50 enrolled1 locationNCT06684379
Recruiting
Phase 1

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above

Respiratory Syncytial Virus Infections
Shenzhen Shenxin Biotechnology Co., Ltd240 enrolled2 locationsNCT06645665
Recruiting
Phase 3

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

Respiratory Syncytial Virus Infections
Kexing Biopharm Co., Ltd.322 enrolled1 locationNCT06363370
Recruiting

Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV

Respiratory Syncytial Virus Infections
Assistance Publique - Hôpitaux de Paris133 enrolled1 locationNCT06197152